Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives $20.00 Average PT from Brokerages

by · The Markets Daily

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) has earned an average rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $20.00.

Several research analysts recently weighed in on ABEO shares. Oppenheimer boosted their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Weiss Ratings lowered Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

Get Our Latest Research Report on Abeona Therapeutics

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock opened at $4.87 on Friday. The company has a market capitalization of $263.91 million, a P/E ratio of 3.96 and a beta of 1.12. The stock has a fifty day simple moving average of $4.98 and a 200 day simple moving average of $5.84. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, sell-side analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Brendan M. O’malley sold 9,366 shares of the firm’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $5.39, for a total transaction of $50,482.74. Following the completion of the sale, the senior vice president owned 350,763 shares in the company, valued at approximately $1,890,612.57. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $4.74, for a total transaction of $71,100.00. Following the completion of the sale, the director directly owned 62,252 shares in the company, valued at approximately $295,074.48. This represents a 19.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 78,612 shares of company stock worth $410,271 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. purchased a new position in Abeona Therapeutics in the second quarter valued at approximately $25,000. Legal & General Group Plc bought a new stake in shares of Abeona Therapeutics in the second quarter valued at $27,000. Russell Investments Group Ltd. bought a new stake in shares of Abeona Therapeutics in the third quarter valued at $37,000. Legato Capital Management LLC purchased a new position in shares of Abeona Therapeutics during the 3rd quarter valued at $57,000. Finally, Riverwater Partners LLC bought a new position in shares of Abeona Therapeutics during the 2nd quarter worth $62,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Stories